Rilonacept Regeneron (previously Arcalyst) Uniunea Europeană - română - EMA (European Medicines Agency)

rilonacept regeneron (previously arcalyst)

regeneron uk limited - rilonacept - sindroamele periodice asociate criopirinei - imunosupresoare - rilonacept regeneron este indicat pentru tratamentul sindroamelor asociate cryopyrin periodice (capace) cu simptome severe, inclusiv sindrom auto-inflamatorii rece familiale (fcas) şi sindromul muckle-wells (dm), la adulţi şi copii cu vârsta de 12 ani şi mai vechi.

LIBTAYO 350 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

libtayo 350 mg

regeneron ireland designated activity company - irlanda - cemiplimabum - conc. pt. sol. perf. - 50mg/ml - anticorpi monoclonali

Libtayo Uniunea Europeană - română - EMA (European Medicines Agency)

libtayo

regeneron ireland designated activity company (dac) - cemiplimab - carcinom, celule scuamoase - agenți antineoplazici - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

CLOPIGAMMA 75 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

clopigamma 75 mg

worwag pharma gmbh & co. kg - clopidogrelum - compr. film. - 75mg - antitrombotice antiagregante plachetare

LENALIDOMIDA SANDOZ 10 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lenalidomida sandoz 10 mg

synthon hispania, s.l. - spania - lenalidomidum - caps. - 10mg - imunosupresoare alte imunosupresoare

LENALIDOMIDA SANDOZ 15 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lenalidomida sandoz 15 mg

synthon hispania, s.l. - spania - lenalidomidum - caps. - 15mg - imunosupresoare alte imunosupresoare

LENALIDOMIDA SANDOZ 2,5 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lenalidomida sandoz 2,5 mg

synthon hispania, s.l. - spania - lenalidomidum - caps. - 2,5mg - imunosupresoare alte imunosupresoare

LENALIDOMIDA SANDOZ 20 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lenalidomida sandoz 20 mg

synthon hispania, s.l. - spania - lenalidomidum - caps. - 20mg - imunosupresoare alte imunosupresoare

LENALIDOMIDA SANDOZ 25 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lenalidomida sandoz 25 mg

synthon hispania, s.l. - spania - lenalidomidum - caps. - 25mg - imunosupresoare alte imunosupresoare

LENALIDOMIDA SANDOZ 5 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lenalidomida sandoz 5 mg

synthon hispania, s.l. - spania - lenalidomidum - caps. - 5mg - imunosupresoare alte imunosupresoare